Use of the Amplatzer vascular occluder to occlude large venous vessels in adults and children with congenital heart disease: A case series

Hares, Dominic; Tometzki, Andrew; Martin, Robin P.

doi:10.1002/ccd.20921

Cited by 12 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The FDA approved the amplatzer vascular plug 1 and 2 for use in May 2004, and September 2007, respectively. Since that time, there have been numerous published reports describing their utility for vascular occlusion procedures in a variety of clinical settings, including the peripheral vasculature [3], pulmonary AVMs [11–13], venous collaterals [14], aorto‐pulmonary collaterals [15], coronary fistulae [16–18], patent ductus ateriosus [7, 19], modified Blalock‐Taussig shunts [20], Fontan fenestrations [21], ventriculo‐pulmonary connections [22], vena cava aneurysms [23], perivalvular leaks [24], and porto‐systemic connections [9, 25]. The majority of these reports are small series that describe the original plug 1 device, with few reports describing plug 2 [4–6].…”

Section: Discussionmentioning

confidence: 99%

The amplatzer vascular plug and amplatzer vascular plug II for vascular occlusion procedures in 50 patients with congenital cardiovascular disease

Schwartz

Glatz

Rome

et al. 2010

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The amplatzer vascular plug and amplatzer vascular plug II for vascular occlusion procedures in 50 patients with congenital cardiovascular disease

Schwartz

Glatz

Rome

et al. 2010

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…If patent ductus arteriosus is not considered, other series on percutaneous occlusion of different VM in pediatric and adult patients include smaller samples and the results are therefore difficult to compare . Larger series have only analyzed the occlusion of pulmonary arteriovenous fistulae, predominantly in adults .…”

Section: Discussionmentioning

confidence: 99%

Percutaneous occlusion of vascular malformations in pediatric and adult patients: 20‐Year Experience of a Single Center

Pereira-da-Silva

Martins

Sousa

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objective: A case series on different vascular malformations (VM) treated with percutaneous occlusion in children and adults is presented. Background: Percutaneous occlusion is usually the preferred treatment method for VM. Previous series have mostly focused on single types of devices and/or VM. Methods: Retrospective analysis of all patients who underwent percutaneous occlusion of VM in a single center, from 1995 to 2014, excluding patent ductus arteriosus. Clinical and angiographic data, procedural details, implanted devices, and complications were assessed. Procedural success was defined as effective device deployment with none or minimal residual flow. Predictors of procedural failure and complications were determined by multivariate analysis. Results: A total of 123 VM were intervened in 47 patients with median age of 12 years (25 days-76 years). The VM included 55 pulmonary arteriovenous fistulae, 39 aortopulmonary collaterals, 10 systemic venovenous collaterals, 8 peripheral arteriovenous fistulae, 5 Blalock-Taussig shunts, 4 coronary fistulae, and 2 Fontan fenestrations. The 143 devices used included 80 vascular plugs, 38 coils, 22 duct occluders, and 3 foramen ovale or atrial septal defect occluders. Median vessel size was 4.5 (2.0-16.0) mm and device/vessel size ratio was 1.4 (1.1-2.0). Successful occlusion was achieved in 118 (95.9%) VM, including three reinterventions. Four (3.3%) clinically relevant complications occurred, without permanent sequelae. Lower body weight was independently associated with procedural failure and complications. Conclusion: To our knowledge, this is the largest series on different VM occluded percutaneously in children and adults, excluding patent ductus arteriosus. Percutaneous occlusion was effective and safe, using different devices. V C 2015 Wiley Periodicals, Inc.

show abstract

“…The clinical conditions in which these vascular plugs are utilized include intracardiac and extracardiac shunts, abnormal arterioarterial, arteriovenous, venovenous malformations, paravalvular leaks, tumor embolization and portosystemic shunts. [78910111213141516171819]…”

Section: Discussionmentioning

confidence: 99%

Amplatzer vascular plugs in congenital cardiovascular malformations

et al. 2013

View full text Add to dashboard Cite

Background:Amplatzer vascular plugs (AVPs) are devices ideally suited to close medium-to-large vascular communications. There is limited published literature regarding the utility of AVPs in congenital cardiovascular malformations (CCVMs).Aims:To describe the use of AVPs in different CCVMs and to evaluate their safety and efficacy.Materials and Methods:All patients who required an AVP for the closure of CCVM were included in this retrospective review of our catheterization laboratory data. The efficacy and safety of AVPs are reported.Results:A total of 39 AVPs were implanted in 31 patients. Thirteen (33%) were AVP type I and 23 (59%) were AVP type II. AVP type III were implanted in two patients and type IV in one patient. The major indications for their use included closure of pulmonary arteriovenous malformation (AVM) (n = 7), aortopulmonary collaterals (n = 7), closure of a patent Blalock-Taussig shunt (n = 5), systemic AVM (n = 5), coronary AVM (n = 4), patent ductus arteriosus (PDA) (n = 3), pulmonary artery aneurysms (n = 3), and venovenous collaterals (n = 2). Deployment of the AVP was done predominantly via the 5 – 7F Judkin's right coronary guide catheter. Overall 92% of the AVPs could be successfully deployed and resulted in occlusion of the target vessel in all cases, within 10 minutes. No procedure-related or access site complication occurred.Conclusions:AVPs are versatile, easy to use, and effective devices to occlude the vascular communications in a variety of settings. AVP II is especially useful in the closure of tubular structures with a high flow.

show abstract

Use of the Amplatzer vascular occluder to occlude large venous vessels in adults and children with congenital heart disease: A case series

Cited by 12 publications

References 15 publications

The amplatzer vascular plug and amplatzer vascular plug II for vascular occlusion procedures in 50 patients with congenital cardiovascular disease

The amplatzer vascular plug and amplatzer vascular plug II for vascular occlusion procedures in 50 patients with congenital cardiovascular disease

Percutaneous occlusion of vascular malformations in pediatric and adult patients: 20‐Year Experience of a Single Center

Amplatzer vascular plugs in congenital cardiovascular malformations

Contact Info

Product

Resources

About